Senaste publikationer

Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?

Mangsbo, Sara M

Ingår i Expert Opinion on Biological Therapy, s. 115-117, 2023.

DOI för Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

Lauren, Ida; Havervall, Sebastian; Ng, Henry; Lord, Martin et al.

Ingår i Immunity, Inflammation and Disease, 2022.

DOI för Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology Ladda ner fulltext (pdf) av Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Marking, Ulrika; Havervall, Sebastian; Greilert-Norin, Nina; Ng, Henry et al.

Ingår i Vaccines, 2022.

DOI för Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines Ladda ner fulltext (pdf) av Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Ellingsen, Espen Basmo; Aamdal, Elin; Guren, Tormod; Lilleby, Wolfgang et al.

Ingår i Journal for ImmunoTherapy of Cancer, 2022.

DOI för Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials Ladda ner fulltext (pdf) av Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19

Havervall, Sebastian; Ng, Henry; Jernbom Falk, August; Greilert-Norin, Nina et al.

Ingår i Journal of Internal Medicine, s. 72-80, 2022.

DOI för Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19 Ladda ner fulltext (pdf) av Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19

Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection

Blom, Kim; Marking, Ulrika; Havervall, Sebastian; Norin, Nina Greilert et al.

Ingår i Lancet. Infectious diseases (Print), s. 943-945, 2022.

DOI för Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection

Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab

Tolf, Andreas; Wiberg, Anna; Müller, Malin; Nazir, Faisal Hayat et al.

Ingår i JAMA Network Open, 2022.

DOI för Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab Ladda ner fulltext (pdf) av Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Ellingsen, Espen Basmo; Bounova, Gergana; Kerzeli, Iliana Kyriaki; Anzar, Irantzu et al.

Ingår i Journal of Translational Medicine, 2022.

DOI för Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination Ladda ner fulltext (pdf) av Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time

Havervall, Sebastian; Marking, Ulrika; Greilert-Norin, Nina; Gordon, Max et al.

Ingår i Clinical & Translational Immunology (CTI), 2022.

DOI för Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time Ladda ner fulltext (pdf) av Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection

Havervall, Sebastian; Falk, August Jernbom; Klingstrom, Jonas; Ng, Henry et al.

Ingår i PLOS ONE, 2022.

DOI för SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection Ladda ner fulltext (pdf) av SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection

An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Eltahir, Mohamed; Lauren, Ida; Lord, Martin; Chourlia, Aikaterini et al.

Ingår i Advanced Therapeutics, 2022.

DOI för An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies Ladda ner fulltext (pdf) av An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Eltahir, mohmo394; Fletcher, E.; Dynesius, L.; Jarblad, J. L. et al.

Ingår i International Immunopharmacology, 2021.

DOI för Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients Ladda ner fulltext (pdf) av Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Havervall, Sebastian; Rosell, Axel; Phillipson, Mia; Mangsbo, Sara et al.

Ingår i Journal of the American Medical Association (JAMA), s. 2015-2016, 2021.

DOI för Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells

Napoleone, Antonino; Laurén, Ida; Linkgreim, Triinu; Dahllund, Leif et al.

Ingår i New Biotechnology, s. 9-19, 2021.

DOI för Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells Ladda ner fulltext (pdf) av Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2

Havervall, Sebastian; Marking, Ulrika; Greilert-Norin, Nina; Ng, Henry et al.

Ingår i EBioMedicine, 2021.

DOI för Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 Ladda ner fulltext (pdf) av Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2

Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

Kerzeli, Iliana Kyriaki; Lord, Martin; Doroszko, Milena; Elgendy, Ramy et al.

Ingår i PLOS ONE, 2021.

DOI för Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations Ladda ner fulltext (pdf) av Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

Mangsbo, Sara; Havervall, Sebastian; Laurén, Ida; Lindsay, Robin et al.

Ingår i PLOS ONE, 2021.

DOI för An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses Ladda ner fulltext (pdf) av An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer

Backman, Max; La Fleur, Linnea; Kurppa, Pinja; Djureinovic, Dijana et al.

Ingår i Journal of Pathology, s. 243-256, 2021.

DOI för Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer Ladda ner fulltext (pdf) av Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Eltahir, Mohamed; Isaksson, Johan; Mattsson, Johanna Sofia Margareta; Karre, Klas et al.

Ingår i Cancers, 2021.

DOI för Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade Ladda ner fulltext (pdf) av Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

van Hooren, Luuk; Vaccaro, Alessandra; Ramachandran, Mohanraj; Vazaios, Konstantinos et al.

Ingår i Nature Communications, 2021.

DOI för Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma Ladda ner fulltext (pdf) av Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Georganaki, Maria; Ramachandran, Mohanraj; Tuit, Sander; Nunez, Nicolas Gonzalo et al.

Ingår i Oncoimmunology, 2020.

DOI för Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy Ladda ner fulltext (pdf) av Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Flodvåg av långtidssjuka covid-19-patienter väntar

Rostedt Punga, Anna; Strömme, Maria; Alimohammadi, Mohammed; Eltahir, Mohammed et al.

Ingår i Dagens Nyheter, s. 5-5, 2020.

Tumor localized agonistic anti-CD40 therapy and beyond

Eltahir, Mohamed; Persson, Helena; Mangsbo, Sara

Ingår i Expert Opinion on Biological Therapy, s. 215-217, 2020.

DOI för Tumor localized agonistic anti-CD40 therapy and beyond

Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention

Nasi, Aikaterini; McArdle, Stephanie; Gaudernack, Gustav; Westman, Gabriel et al.

Ingår i Toxicology reports, s. 768-771, 2020.

DOI för Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention Ladda ner fulltext (pdf) av Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention

BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling

Ibarra, Cristian; Karlsson, Marie; Codeluppi, Simone; Varas-Godoy, Manuel et al.

Ingår i Molecular Oncology, s. 202-211, 2019.

DOI för BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling Ladda ner fulltext (pdf) av BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling

Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses

Mangsbo, Sara; Fletcher, Erika; van Maren, Wendy; Redeker, Anke et al.

Ingår i Molecular Immunology, s. 115-124, 2018.

DOI för Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System

Fletcher, Erika; van Maren, Wendy; Cordfunke, Robert; Dinkelaar, Jasper et al.

Ingår i Journal of Immunology, s. 87-97, 2018.

DOI för Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System

Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics

Fletcher, Erika A. K.; Eltahir, Mohamed; Lindqvist, Frida; Rieth, Jonas et al.

Ingår i International Immunopharmacology, s. 1-11, 2018.

DOI för Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics Ladda ner fulltext (pdf) av Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Eriksson, Emma; Moreno, R; Milenova, I. Yoanna; Liljenfeldt, L et al.

Ingår i Gene Therapy, s. 92-103, 2017.

DOI för Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment Ladda ner fulltext (pdf) av Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Svensson, Emma et al.

Ingår i Journal of Translational Medicine, 2017.

DOI för Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients Ladda ner fulltext (pdf) av Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Eriksson, Emma et al.

Ingår i Scandinavian Journal of Immunology, s. 337-337, 2017.

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

van Hooren, Luuk; Sandin, Linda C.; Moskalev, Igor; Ellmark, Peter et al.

Ingår i European Journal of Immunology, s. 385-393, 2017.

DOI för Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Irenaeus, Sandra; Schiza, Aglaia; Mangsbo, Sara M.; Wenthe, Jessica et al.

Ingår i OncoTarget, s. 78573-78587, 2017.

DOI för Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients Ladda ner fulltext (pdf) av Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Selective Fc gamma R engagement by human agonistic anti-CD40 antibodies

Ellmark, Peter; Mangsbo, Sara M.; Lindstedt, Malin

Ingår i Translational Cancer Research, s. S839-S841, 2016.

DOI för Selective Fc gamma R engagement by human agonistic anti-CD40 antibodies

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment

van Hooren, Luuk; Georganaki, Maria; Huang, Hua; Mangsbo, Sara M. et al.

Ingår i OncoTarget, s. 50277-50289, 2016.

DOI för Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment Ladda ner fulltext (pdf) av Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Ingår i British Journal of Cancer, s. 872-880, 2016.

DOI för Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity

Mangsbo, Sara M; Broos, Sissela; Fletcher, Erika; Veitonmäki, Niina et al.

Ingår i Clinical Cancer Research, s. 1115-1126, 2015.

DOI för The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Christiansson, Lisa; Söderlund, Stina; Mangsbo, Sara; Hjorth-Hansen, Henrik et al.

Ingår i Molecular Cancer Therapeutics, s. 1181-1191, 2015.

DOI för The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Kick-starting the cancer-immunity cycle by targeting CD40

Ellmark, P.; Mangsbo, Sara M.; Furebring, C.; Tötterman, Thomas H. et al.

Ingår i Oncoimmunology, 2015.

DOI för Kick-starting the cancer-immunity cycle by targeting CD40

Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells

Vogel, Stephanie; Grabski, Elena; Buschjaeger, Daniela; Klawonn, Frank et al.

Ingår i Scientific Reports, 2015.

DOI för Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells Ladda ner fulltext (pdf) av Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

Liljenfeldt, Lina; Dieterich, Lothar C.; Dimberg, Anna; Mangsbo, Sara M. et al.

Ingår i Cancer Gene Therapy, s. 95-102, 2014.

DOI för CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention

Burman, Joachim; Svensson, Emma; Fransson, Moa; Loskog, Angelica S I et al.

Ingår i Journal of Neuroimmunology, s. 153-159, 2014.

DOI för The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention

Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis

Burman, Joachim; Svensson, Emma; Fransson, Moa; Loskog, Angelica et al.

Ingår i Journal of Neuroimmunology, s. 141-141, 2014.

DOI för Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis

FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis

Yilmaz-Elis, A Seda; Ramirez, Javier Martin; Asmawidjaja, Patrick; van der Kaa, Jos et al.

Ingår i Journal of Immunology, s. 5540-5547, 2014.

DOI för FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer

Sandin, Linda; Orlova, Anna; Gustafsson, Erika; Ellmark, Peter et al.

Ingår i Cancer Immunology Research, s. 80-90, 2014.

DOI för Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer Ladda ner fulltext (pdf) av Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer

AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Ingår i Molecular Therapy, s. S247-S247, 2014.

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Christiansson, Lisa; Mustjoki, Satu; Simonsson, Bengt; Olsson-Strömberg, Ulla et al.

Ingår i EuPA Open Proteomics, s. 37-47, 2014.

DOI för The use of multiplex platforms for absolute and relative protein quantification of clinical material

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Sandin, Linda C.; Eriksson, Fredrik; Ellmark, Peter; Loskog, Angelica S. I. et al.

Ingår i Oncoimmunology, s. e2761-, 2014.

DOI för Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer

Sandin, Linda C.; Tötterman, Thomas H.; Mangsbo, Sara M.

Ingår i Oncoimmunology, 2014.

DOI för Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer

A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells

Liljenfeldt, Lina; Yu, Di; Chen, Liye; Essand, Magnus et al.

Ingår i Journal of immunotherapy (1997), s. 155-162, 2014.

DOI för A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells